posted on 2023-04-04, 01:45authored byJason Roszik, J. Jack Lee, Yi-Hung Wu, Xi Liu, Masanori Kawakami, Jonathan M. Kurie, Anas Belouali, Simina M. Boca, Samir Gupta, Robert A. Beckman, Subha Madhavan, Ethan Dmitrovsky
Supplementary Table 5: The MD Anderson and Georgetown cohorts 5-year survival rates and differences of 5-year restricted mean survival time in months between NSAID users and non-users for all patients and by stage and histopathology corresponding to Figure 1. The abbreviations are AD (adenocarcinoma) and SCC (squamous cell cancer), respectively.
Funding
HHS | National Institutes of Health (NIH)
Samuel Waxman Cancer Research Foundation (SWCRF)
University of Texas System (UT)
American Cancer Society (ACS)
History
ARTICLE ABSTRACT
NLP and real-world studies conducted in large cohorts explored whether NSAIDs improved survival across NSCLC stages, histopathology, gender, smoking history, or demographic groups. A statistically significant association between NSAID use and NSCLC survival was found. This provides a rationale for future NSAID randomized NSCLC trials.